Preliminary results of surufatinib (Suru) plus standard chemotherapy (ChT) as second line (2L) treatment of advanced gastric cancer (aGC): A single-arm, phase 2 clinical trial.

被引：0
|
作者：
Han, Ting [1 ]
Lin, Xiaolin [1 ]
Zhuo, Meng [1 ]
Jiao, Feng [1 ]
Cui, Jiujie [1 ]
Qiu, Xiaoxia [1 ]
Xiao, Xiuying [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.3_suppl.353
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：353 / 353
页数：1
相关论文
共 50 条
  • [41] Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
    Meng, Xiangrui
    Wu, Tao
    Hong, Yonggui
    Fan, Qingxia
    Ren, Zhonghai
    Guo, Yanzhen
    Yang, Xiuli
    Shi, Pei
    Yang, Jiamei
    Yin, Xianzhe
    Luo, Zhiquan
    Xia, Jin
    Zhou, Yue
    Xu, Mengli
    Liu, Enjie
    Jiang, Guozhong
    Li, Shenglei
    Zhao, Feng
    Ma, Chi
    Ma, Chuanxiang
    Hou, Zhiguo
    Li, Jing
    Wang, Junsheng
    Wang, Feng
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (03): : 245 - 253
  • [42] Camrelizumab plus concurrent chemoradiotherapy for locally advanced cervical cancer: Preliminary results of a single-arm, open-label, phase II trial
    Xiao, Y.
    Cheng, H.
    Wang, L.
    Yang, L.
    Yu, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S805 - S805
  • [43] DKN-01 plus bevacizumab and chemotherapy as second-line (2L) investigational therapy in advanced microsatellite stable (MSS) colorectal adenocarcinoma (CRC): DeFianCe trial.
    Pelster, Meredith
    Strickler, John H.
    Sirard, Cynthia A.
    Baum, Jason
    Haas, Mike
    Devoe, Craig E.
    Bustamante, Liliana
    Bubis, Jeffrey Alan
    Womack, Mark Sanders
    Wainberg, Zev A.
    Chung, Ki Y.
    Raff, Joshua P.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 104 - 104
  • [44] A Phase 2 Pilot Single-Arm Prospective Clinical Trial of the STAT RAD Workflow for Osseous Metastases: Preliminary Results
    Wilson, D. D.
    Sim, A.
    Handsfield, L. L.
    Chen, Q.
    Blackball, L.
    Showalter, T. N.
    Read, P. W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S563 - S563
  • [45] Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): Preliminary results of a single-arm, multicenter phase II trial
    Li, H.
    Zhou, D.
    Yv, Z.
    Liao, Y.
    Huang, J.
    Sun, S.
    Zheng, F.
    Li, B.
    Fang, S.
    Qiang, L.
    Ren, G.
    Wang, X.
    Baoxuan, Z.
    Fan, B.
    Zhao, X.
    Li, W.
    Wang, Z.
    Fu, H.
    Sun, X.
    Shi, Z.
    ANNALS OF ONCOLOGY, 2024, 35 : S381 - S381
  • [46] Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): preliminary results of a single-arm, multicenter phase II trial
    Li, Huihui
    Tan, Qiaorui
    Sun, Shujuan
    Zhou, Dongdong
    Yu, Bo
    Su, Mu
    Li, Baojiang
    Fang, Shu
    Qiang, Ling
    Ren, Guohua
    Bu, Bing
    Yin, Sha
    Man, Xiaochu
    Qiu, Pengfei
    Wang, Xinzhao
    Li, Chao
    Cao, Fangli
    Shao, Qian
    Han, Dali
    Song, Lihua
    Fan, Bingjie
    Zhang, Baoxuan
    Xu, Liang
    Zhao, Xianguang
    Liao, Yuqian
    Xie, Xuemei
    Liu, Lanping
    CANCER RESEARCH, 2023, 83 (05)
  • [47] Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): preliminary results of a single-arm, multicenter phase II trial
    Li, Huihui
    Zhou, Dongdong
    Yv, Zeshun
    Liao, Yuqian
    Huang, Jie
    Sun, Shujuan
    Zheng, Fangchao
    Li, Baojiang
    Fang, Shu
    Qiang, Ling
    Ren, Guohua
    Bu, Bing
    Qiu, Pengfei
    Wang, Xinzhao
    Li, Chao
    Cao, Fangli
    Shao, Qian
    Han, Dali
    Song, Lihua
    Zhang, Baoxuan
    Fan, Bingjie
    Xu, Liang
    Xie, Xuemei
    Zhao, Xianguang
    Liu, Lanping
    Li, Wanlong
    Wang, Zhenbo
    Liu, Changmin
    Fu, Hui
    Sun, Xiao
    Shi, Zhiqiang
    Li, Fengxiang
    CANCER RESEARCH, 2024, 84 (09)
  • [48] An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal Cancer
    Cohn, Allen L.
    Shumaker, Grace C.
    Khandelwal, Pankaj
    Smith, David A.
    Neubauer, Marcus A.
    Mehta, Nilesh
    Richards, Donald
    Watkins, David L.
    Zhang, Kathy
    Yassine, Mohamed R.
    CLINICAL COLORECTAL CANCER, 2011, 10 (03) : 171 - 177
  • [49] Preliminary results of benmelstobart plus anlotinib combined with SOX in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with low PD-L1 expression: A single-arm, multicenter phase II clinical trial
    Jia, Yong-Xu
    Chang, Zhiwei
    Zhong, Ya-Li
    Cui, Donghai
    Han, Hui-Qiong
    Gao, Ya-Ping
    He, Jian
    Liu, Xiao-Lei
    Yan, Jie
    Qin, Yanru
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 444 - 444
  • [50] Apatinib plus etoposide as second-or higher-line treatment in recurrent or metastatic triple-negative breast cancer: A single-arm, open label, prospective, phase II clinical trial.
    Cao, Mengru
    Lu, Hailing
    Yan, Shi
    Pang, Hui
    Sun, Lichun
    Li, Chunhong
    Chen, Xuesong
    Liu, Wei
    Hu, Jing
    Huang, Jian
    Xing, Ying
    Chen, Yingqi
    He, Ting
    Zhao, Danni
    Sun, Yuanyuan
    Zhao, Lin
    Liu, Xiaomeng
    Zhang, Ningzhi
    Cai, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345